Recurrent and second primary squamous cell carcinoma of the head and neck: When and how to reirradiate
Strojan, Primož; Corry, June; Eisbruch, Avraham; Vermorken, Jan B.; Mendenhall, William M.; Lee, Anne W. M.; Haigentz, Missak; Beitler, Jonathan J.; Bree, Remco; Takes, Robert P.; Paleri, Vinidh; Kelly, Charles G.; Genden, Eric M.; Bradford, Carol R.; Harrison, Louis B.; Rinaldo, Alessandra; Ferlito, Alfio
2015-01
Citation
Strojan, Primož ; Corry, June; Eisbruch, Avraham; Vermorken, Jan B.; Mendenhall, William M.; Lee, Anne W. M.; Haigentz, Missak; Beitler, Jonathan J.; Bree, Remco; Takes, Robert P.; Paleri, Vinidh; Kelly, Charles G.; Genden, Eric M.; Bradford, Carol R.; Harrison, Louis B.; Rinaldo, Alessandra; Ferlito, Alfio (2015). "Recurrent and second primary squamous cell carcinoma of the head and neck: When and how to reirradiate." Head & Neck 37(1): 134-150.
Abstract
Background Local and/or regional recurrence and metachronous primary tumor arising in a previously irradiated area are rather frequent events in patients with head and neck squamous cell carcinoma (HNSCC). Re‐treatment is associated with an increased risk of serious toxicity and impaired quality of life (QOL) with an uncertain survival advantage. Methods We analyzed the literature on the efficacy and toxicity of photon/electron‐based external beam reirradiation for previously irradiated patients with HNSCC of non‐nasopharyngeal origin. Studies were grouped according to the radiotherapy technique used for reirradiation. Patient selection criteria, target volume identification method, tumor dose, fractionation schedule, systemic therapy administration, and toxicities were reviewed. Results In addition to disease‐related factors, current comorbidities and preexisting organ dysfunction must be considered when selecting patients for reirradiation. As morbidity from re‐treatment may be considerable and differ depending on which mode of re‐treatment is used, it is important to give patients information on potential morbidity outcomes so that an informed choice can be made within a shared decision‐making context. With improved dose distribution and adequate imaging support, including positron emission tomography‐CT, modern radiotherapy techniques may improve local control and reduce toxicity of reirradiation. A reirradiation dose of ≥60 Gy and a volume encompassing the gross tumor with up to a 5‐mm margin are recommended. Concomitant administration of systemic therapeutics and reirradiation is likely to be of similar benefit as observed in large randomized studies of upfront therapy. Conclusion Reirradiation, administered either with or without concurrent systemic therapy, is feasible and tolerable in properly selected patients with recurrent or a new primary tumor in a previously irradiated area of the head and neck, offering a meaningful survival (in the range of 10% to 30% at 2 years). Whenever feasible, salvage surgery is the method of choice for curative intent; patients at high‐risk for local recurrence should be advised that postoperative reirradiation is expected to increase locoregional control at the expense of higher toxicity and without survival advantage compared to salvage surgery without reirradiation. © 2014 Wiley Periodicals, Inc. Head Neck 37 : 134–150, 2015Publisher
Wiley Periodicals, Inc.
ISSN
1043-3074 1097-0347
Other DOIs
Types
Article
Metadata
Show full item recordCollections
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.